LAR tumors are characterized to be highly aggressive [152,153], which has emphasized the need for clarifying the role of AR in BC and promoted the development of several AR antagonists that are currently being tested in multiple clinical trials alone or in combination with other treatment strategies for ER− BC, which have been comprehensively reviewed by other authors [108,154,155,156]. This evidence concerns the gene AR and breast cancer.